Fulcrum Therapeutics to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Rhea-AI Summary

Fulcrum Therapeutics, Inc. will present a corporate overview at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The webcast of the presentation will be accessible on the company's website. The management will also participate in one-on-one investor meetings.

CAMBRIDGE, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will present a corporate overview at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, being held virtually on Tuesday, February 13, 2024 at 1:20 p.m. ET. Management will also participate in one-on-one investor meetings.

The webcast of the presentation will be accessible here and by visiting the "Events and Presentations" section of Fulcrum Therapeutics’ website at https://ir.fulcrumtx.com/events-and-presentations. A replay of the webcast will be available on Fulcrum Therapeutics’ website for at least 30 days following the presentation.

About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule in development for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and pociredir, a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD) and other hemoglobinopathies. Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.

Contact:
Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com 
917-680-5608

FAQ

When and where will Fulcrum Therapeutics, Inc. present a corporate overview?

Fulcrum Therapeutics, Inc. will present a corporate overview at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, being held virtually on Tuesday, February 13, 2024 at 1:20 p.m. ET.

How can the webcast of the presentation be accessed?

The webcast of the presentation will be accessible on Fulcrum Therapeutics’ website at https://ir.fulcrumtx.com/events-and-presentations.

Will there be a replay of the webcast available?

A replay of the webcast will be available on Fulcrum Therapeutics’ website for at least 30 days following the presentation.